InMode Expects Record Fourth Quarter and Full Year 2020 Results, Fourth Quarter Revenue Between $74.5-$75M, Non-GAAP Earnings per Diluted Share Between $0.91-$0.93; Announces 2021 Full Year Revenue Guidance of $250- $260M


2021-01-14 01:00:28 BioSpace


Conference call to be held on February 10 at 8:30 a.m. Eastern Time InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2020 before the Nasdaq market opens on Wednesday, February 10, 2021. InMode is currently finalizing its financial results for the three months and year ended December 31, 2020. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of InMode's financial results for such period, subject to final adjustments and other developments that may arise between now and the time such financial results are finalized. Based on preliminary results, management expects: Record revenue for the fourth quarter and full year of 2020 in the range of $74.5 million to $75 million and $205.5 million to $206 million, respectively, higher than the previously announced guidance of $192 million to $195 million Non-GAAP earnings per diluted share for the fourth quarter and full year of 2020 in the range of $0.91 to $0.93 and $2.08 to $2.10, respectively Non-GAAP gross margin for the full year of 2020 in the range of 84% to 86% Full year 2021 revenue guidance in the range of $250 million to $260 million. "Our best-in-class sales and marketing team adapted to the new COVID environment seamlessly. We were able to execute on all of our strategic goals throughout the ongoing pandemic. Our unique hands-free and minimally invasive technology supported InMode's growth by providing safe and effective solutions for physicians to offer their patients," commented Moshe Mizrahy, InMode's CEO. "Our new proprietary and patented technologies have been well-accepted by the medical community even during this difficult period. These technologies enabled physicians to provide solutions that maintain social distancing for out-patient clinic-based treatments. We believe these treatments are becoming the standard of care in the COVID-19 environment," commented Dr. Michael Kreindel, InMode's CTO. [1] Please refer to "Use of Non-GAAP Financial Measure" below for important information about non-GAAP financial measures. Non-GAAP financial results exclude stock-based compensation and related tax adjustments. Members of InMode's management team will host a conference call to discuss the fourth quarter and full year 2020 financial results on February 10, 2021, at 8:30 a.m. Eastern Time. The presenters include Mr. Moshe Mizrahy, Chairman and Chief Executive Officer; Dr. Michael Kreindel, co-founder and Chief Technology Officer; Mr. Yair Malca, Chief Financial Officer; Mr. Shakil Lakhani, President of North America; and Dr. Spero Theodorou, Chief Medical Officer. The Company encourages participants to pre-register for the conference call using the following link: Callers will receive a unique dial-in upon registration, which enables immediate access on the day of the call. Participants may pre-register at any time, including up to and after the call start time. For callers that opt out of pre-registration, please dial one of the following teleconferencing numbers. Please begin by placing your call 10 minutes before the conference call commences. If you are unable to connect using the toll-free number, please try the international dial-in number. U.S. Toll-Free: 1-833-316-0562 Israel Toll-Free: 1-80-921-2373 International: 1-412-317-5736 At: 8:30 a.m. Eastern Time 5:30 a.m. Pacific Time 3:30 p.m. Israel Time The conference call will also be webcast live from a link on InMode's website at A replay of the conference call will be available from February 10, 2021 at 12:00 p.m. Eastern Time to February 24, 2021 at 11:59 p.m. Eastern Time. To access the replay, please dial one of the following numbers: Replay U.S. TOLL-FREE: 1-877-344-7529 Replay Canada TOLL-FREE: 855-669-9658 Replay TOLL/INTERNATIONAL: 1-412-317-0088 Replay Pin Number: 10151158 A replay will also be available for 90 days on InMode's website at: About InMode InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit Use of Non-GAAP Financial Measure This release includes an estimate of InMode's expected non-GAAP earnings per diluted share for the fourth quarter and full year 2020. Because this financial measure is used in InMode's internal analysis of financial and operating performance, management believes that it provides greater transparency to investors of management's view of InMode's economic performance. Management also believes the presentation of this measure allows investors to more effectively evaluate and compare the performance of InMode to that of its peers, although InMode's presentation of this non-GAAP measure may not be comparable to other similarly-titled measures of other companies. InMode has not provided a reconciliation of non-GAAP earnings per diluted share to the corresponding GAAP financial measure on a forward-looking basis due to the potential variability, limited visibility and unpredictability. See "Forward-Looking Statements" for additional information. Forward-Looking Statements This press release contains certain forward-looking statements. Words such as "expects" and "strives" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to the inherent uncertainties in predicting future results and conditions, many of which are beyond the control of InMode, including, without limitation, risks relating to the impact of the COVID-19 outbreak and the risk factors and other matters set forth in its Annual Report on Form F-20 for the year ended December 31, 2019 filed with the Securities and Exchange Commission on February 18, 2020. The COVID-19 outbreak has caused significant volatility and disruption in the financial markets both globally and in the United States. If COVID-19 continues to spread or the response to contain it is unsuccessful, InMode could experience material adverse effects on its business, financial condition, liquidity and results of operations. InMode undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law. Investor Relations Contact: Miri Segal-Scharia MS-IR LLC 917-607-8654 multimedia:
美国东部时间2月10日上午8:30召开电话会议 全球领先的创新医疗技术供应商InMode Ltd.(纳斯达克市场代码:INMD)今天宣布,预计将在2021年2月10日(星期三)纳斯达克市场开市前发布第四季度和2020年全年的财务业绩。 InMode目前正在敲定截至2020年12月31日止三个月及年度的财务业绩。虽然尚未获得完整的财务信息和运营数据,但下文列出了Inmode在该期间的财务结果的某些初步结果,但仍需进行最终调整,以及从现在到该财务结果最终确定之时可能出现的其他发展。根据初步结果,管理层预计: 第四季度和2020年全年的创纪录收入分别为7450万至7500万英镑和2.055亿至2.06亿英镑,高于此前公布的1.92亿至1.95亿英镑的预期 第四季度和2020年全年的非GAAP每股摊薄收益分别在0.91-0.93和2.08-2.10之间 2020年全年的非GAAP毛利率范围为84%至86% 2021年全年收入指引范围在2.5亿至2.6亿之间。 Inmode首席执行官Moshe Mizrahy说:“我们一流的销售和营销团队无缝地适应了新的贪婪环境。我们能够在疫情持续期间执行我们的所有战略目标。我们独特的免提和微创技术通过为医生提供安全有效的解决方案来支持Inmode的发展。” inmode's cto Michael Kreindel博士说:即使在这个困难时期,我们新的专有和专利技术已经被医学界广泛接受。这些技术使医生能够为门诊病人的临床治疗提供维持社会距离的解决方案。我们相信这些治疗正在成为COVID-19环境中的护理标准。 [1]关于非一般公认会计原则财务措施的重要信息,请参阅下文“非一般公认会计原则财务措施的使用”。非GAAP财务结果不包括基于股票的薪酬和相关的纳税调整。 Inmode's管理团队成员将于美国东部时间2021年2月10日上午8:30召开电话会议,讨论第四季度和2020年全年的财务结果。出席的嘉宾包括主席兼行政总裁Moshe Mizrahy先生;Michael Kreindel博士,联合创始人兼首席技术官;Yair Malca先生,首席财务官;北美洲总裁沙基尔·拉哈尼先生;以及首席医疗官斯伯罗西奥多罗医生。 该公司鼓励与会者使用以下链接预先注册电话会议:。呼叫者在注册时将收到一个唯一的拨入,从而能够在呼叫当天立即访问。参与者可以在任何时间进行预注册,包括在呼叫开始时间之前和之后。 对于选择退出预注册的来电者,请拨打下列电话会议号码之一。请在电话会议开始前10分钟拨打您的电话。如果您无法使用免费号码连接,请尝试国际拨入号码。 美国免费电话:1-833-316-0562 以色列免费电话:1-80-921-2373 国际:1-412-317-5736 在: 东部时间上午8:30 太平洋时间早上5:30 以色列时间下午3时30分 电话会议还将通过Inmode网站的链接进行现场直播,网址是。电话会议的重播将从美国东部时间2021年2月10日中午12:00到美国东部时间2021年2月24日晚上11:59提供。要访问重播,请拨下列号码之一: 重播美国免费电话:1-877-344-7529 重播加拿大免费电话:855-669-9658 重播收费/国际:1-412-317-0088 重播Pin号码:10151158 还将在Inmode的网站上播放90天的重播:。 关于InMode InMode是全球领先的创新医疗技术提供商。InMode开发,制造和销售利用新型射频(RF")技术的设备。InMode致力于使新出现的外科手术以及改进现有的治疗方法成为可能。InMode利用其医学上公认的微创射频技术,为整形外科,妇科,皮肤科,耳鼻喉科和眼科等领域提供了一系列全面的产品。 有关InMode的更多信息,请访问。 非GAAP财务计量的使用 本次发布包括对Inmode公司第四季度和2020年全年每股非公认会计准则摊薄后预期收益的估计。由于在Inmode对财务和经营业绩的内部分析中使用了这一财务衡量标准,管理层认为这为管理层对Inmode经济业绩的看法的投资者提供了更大的透明度。管理层还认为,尽管InMode对这一非GAAP衡量标准的表述可能无法与其他公司的其他类似标题衡量标准相比,但该衡量标准的表述允许投资者更有效地评估和比较InMode与其同行的业绩。由于潜在的可变性,有限的可见性和不可预见性,InMode没有在前瞻性基础上提供非GAAP每股摊薄收益与相应的GAAP财务计量的对账。有关更多信息,请参见“前瞻性陈述”。 前瞻性陈述 本新闻稿包含某些前瞻性陈述。诸如“期望”和“努力”之类的词语或类似的表达方式意在识别前瞻性陈述。这些前瞻性陈述受制于预测未来结果和条件的内在不确定性,其中许多不确定性是InMode无法控制的,包括但不限于与COVID-19爆发的影响相关的风险,以及2020年2月18号提交给证券交易委员会的截至2019年12月31日的年度F-20表中列出的风险因素和其他事项。COVID-19病毒的爆发给全球和美国的金融市场造成了重大的波动和混乱。如果COVID-19继续蔓延或遏制措施不成功,InMode可能会对其业务,财务状况,流动性和运营结果产生重大不利影响。InMode不承担公开更新或修改任何前瞻性陈述的义务,不论是由于新信息,未来事件或其他原因,除非法律要求。 投资者关系联系人: 米里·塞加尔-沙里亚 MS-IR有限责任公司 917-607-8654 多媒体: